Exclusive Interview: Dr. William A. Carter, CEO. Hemispherx Biopharma, Inc. (AMEX:HEB)

Print E-mail
By M.E.Garza   
Friday, 12 June 2009 20:48

Dr.William A. Carter, the CEO of Hemispherx Biopharma shares his thoughts on the FDA delay, the flu pandemic and the future of his company. Late in the interview he also answers questions submitted to us by our readers. Certainly, the interview is filled with candid revelations and interesting nuggets of new information.

Warning: Due To Heavy Traffic And Length, The Screen May Not Load For A Few Seconds. Please Be Patient.
We also have an alternate feed available if you find that this feed is slow to load.

TRT: Approximately 45 Minutes







BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
BioMedReports Array Biopharma Announces Binimetinib Continues to Advance in Clinical Development; Protalix Announces Data on... http://t.co/MgEITGxN8h
10hreplyretweetfavorite
BioMedReports Healthcare Review: Intuitive Surgical, Allergan, Alexion Pharmaceuticals, Zogenix, Biogen Idec: U.S. stocks de... http://t.co/zAmFpC8phs
15hreplyretweetfavorite
BioMedReports Hundreds of genetic mutations found in healthy blood of a supercentenarian http://t.co/tWuJPMOE15
17hreplyretweetfavorite
navigation
Benzinga.com supporter Seeking Alpha Certified